Kaimi Biotech and Scenesafe to Launch Unow™ Drug Residue Test Device in Canada

[Halifax, NS], Canada – [20th May, 2025] – Taizhou Kaimi Biotech Co., Ltd., a global leader in advanced diagnostic technologies, and Scenesafe Trauma Scene Remediation, Canada’s trusted name in biohazard remediation and safety services, today announced a strategic partnership to introduce the Unow™ Drug Residue Test Device across Canada. This cutting-edge portable testing solution is designed to address growing concerns around drug contamination in public spaces, healthcare settings, and law enforcement operations.

Revolutionizing Drug Residue Detection

The Unow™ device empowers users to swiftly identify trace amounts of illicit substances, including opioids, fentanyl, methamphetamine, and other hazardous residues, with laboratory-grade accuracy. Its user-friendly design delivers results in minutes, making it an essential tool for:  

- Law enforcement: Rapid on-site testing during investigations. 

- Healthcare facilities: Ensuring drug-free environments for patient care. 

- Remediation teams: Validating decontamination efforts post-trauma or crime scenes.

- Property managers: Safeguarding residential and commercial spaces.

A Partnership Rooted in Safety and Innovation

By combining Taizhou Kaimi Biotech’s expertise in biotech innovation with Scenesafe’s deep understanding of Canadian safety protocols, the collaboration aims to set a new standard for drug residue detection and remediation.  

Quotes from Leadership

Otis Zhao, President & Founder of Taizhou Kaimi Biotech Co., Ltd., stated: “Our mission is to develop technologies that protect communities worldwide. The Unow™ device represents a leap forward in portable diagnostics, and partnering with Scenesafe ensures this solution meets the unique needs of Canadian markets. Together, we’re tackling a critical public health challenge head-on.”  

Hang Ai, Founder of Scenesafe Trauma Scene Remediation, added: “Drug contamination poses serious risks to first responders, families, and businesses. With Unow™, we can now offer clients immediate, reliable verification of safe environments. This partnership underscores our commitment to leveraging innovation for safer communities.”  

Market Availability

The Unow™ Drug Residue Test Device will be available to Canadian clients starting Q2 /2025, with pre-orders opening soon. For inquiries, contact Scenesafe Trauma Scene Remediation at Halifax@scenesafe.ca.

About the Companies

Taizhou Kaimi Biotech Co., Ltd.(China) specializes in advanced biomedical solutions, including diagnostic devices and biotechnology R&D. Learn more at www.kaimibio.com. 

Scenesafe Trauma Scene Remediation(Canada) provides certified biohazard cleanup, decontamination, and safety consulting services nationwide. Visit www.scenesafe.ca for details.

--- 

This press release is distributed jointly by Taizhou Kaimi Biotech Co., Ltd. and Scenesafe Trauma Scene Remediation.

Exhibitor Data Sheet